Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated the augmentation of venlafaxine with hormone therapy in the treatment of postmenopausal depression. The hormones evaluated were estrogen (0.625 mg) in combination with medroxyprogesterone acetate (2.5 mg) and methyltestosterone (2.5 mg). DESIGN: Seventy-two menopausal women (mean age: 53.6 +/- 4.27 years) diagnosed with depression (Montgomery-Asberg Depression Rating Scale [MADRS] scores > or = 20) were treated with venlafaxine and one of the following hormone therapy combinations, in a double-blind regimen: estrogen + medroxyprogesterone + methyltestosterone (group 1, n = 20); estrogen + medroxyprogesterone acetate (group 2, n = 20); methyltestosterone only (group 3, n = 16); and no hormone therapy (group 4, n = 16). Study duration was 24 weeks. Primary efficacy outcome was remission according to the MADRS, whereas secondary efficacy measures included the Clinical Global Impression (CGI), Blatt-Kupperman Index, and Women's Health Questionnaire (WHQ). RESULTS: Forty-eight patients completed the study. All groups showed significant improvement from baseline. Group 3 demonstrated significant improvement on the MADRS compared with placebo (group 4) at weeks 20 (P = 0.048) and 24 (P = 0.030); effect size 8.04 (0.83; 15.26) (P = 0.029), but also had the highest dropout rate. Groups 1 and 3 had significant CGI improvement rates compared with placebo: 42.23% (P = 0.012) and 44.45% (P = 0.08), respectively. There were no differences in the WHQ or BKI scores among the groups. CONCLUSIONS: Methyltestosterone 2.5 mg had the highest effect size compared with placebo, but the high dropout rate prevented its efficacy from being determined. Estrogen plus medroxyprogesterone, combined with methyltestosterone or otherwise, demonstrated a trend toward increased efficacy of venlafaxine. Further larger-scale clinical trials are needed to elucidate the findings of this pilot study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
Kessler, R. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90026-g · Cited by 2,207 · cited 1×
“E pidemiological data have demonstrated a higher incidence of depression in women, supporting the hypothesis that steroid hormones might play a role in women_s vulnerability to mood disorders.(1,2) Moreover, certain types of mood disorders, including premenstrual dysphoric disorder, postpartum depression, and postmeno…”
BackgroundLingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 1×
“were assessed at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 with the Ugvald for Klinike UndersgelerVSide Effects (UKU) scale.(33)”
MethodEffects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales, A. J., Nolan, J. J., Nelson, J. C., & Yen, S. S. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.7515387 · Cited by 841 · cited 1×
“In a double-blind controlled study, DHEA improved mood in women of different ages, and was associated with well-being in women between 40 and 60 years of age.(57) In another study(58) there was a significant response after 3 weeks of treatment, with improvement in anhedonia, lack of energy, lack of motivation, and emo…”
BackgroundNeuroactive steroids: mechanisms of action and neuropsychopharmacological properties
Rupprecht, R. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00064-1 · Cited by 427
Double-blind treatment of major depression with dehydroepiandrosterone.
Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., & Roberts, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.646 · Cited by 411 · cited 1×
“therapy, a significant improvement in the group receiving DHEA-S was observed.(59) Nevertheless, the”
BackgroundDehydroepiandrosterone treatment of midlife dysthymia∗∗See accompanying Editorial, in this issue.
Bloch, M., Schmidt, P. J., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00066-9 · Cited by 179
Dobs, A. S., Nguyen, T., Pace, C., & Roberts, C. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8362 · Cited by 168
Endogenous concentrations of DHEA and DHEA-S Decrease with remission of depression in older adults
Fabian, T. J., Dew, M. A., Pollock, B. G., Reynolds, C. F., Mulsant, B. H., Butters, M. A., Zmuda, M. D., Linares, A. M., Trottini, M., & Kroboth, P. D. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01198-2 · Cited by 87
Cited by
Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30189-5 · Cited by 278
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
“rate (one-thirdof thesample [135]) andbaselinedifferences in”
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Metadata
- Authors
- Dias, R. S., Kerr-Corrêa, F., Moreno, R. A., Trinca, L. A., Pontes, A., Halbe, H. W., Gianfaldoni, A., & Dalben, I. S.
- Venue
- Menopause
- Published
- 2006-03
- Volume
- 13
- Issue
- 2
- Pages
- 202-211
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W1979844088
- Cited by
- 34
- References
- 9
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. https://app.cochat.ai/papers/10.1097/01.gme.0000198491.34371.9c
- The paper
- Dias, R. S., Kerr-Corrêa, F., Moreno, R. A., Trinca, L. A., Pontes, A., Halbe, H. W., Gianfaldoni, A., & Dalben, I. S. (2006). Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause. https://doi.org/10.1097/01.gme.0000198491.34371.9c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.